title: [Effects of telmisartan and pyridoxamine on abdominal aorta vascular remodeling in spontaneously hypertensive rats].
abstract: OBJECTIVE
  To investigate the effects of telmisartan and pyridoxamine on vascular smooth muscle cells (VSMCs) proliferation and apoptosis as well as abdominal aorta vascular remodeling in spontaneously hypertensive rats (SHRs).
  
  
  METHODS
  SHRs randomly received placebo, telmisartan (6 mg kg(-1) x d(-1)), pyridoxamine (200 mg x kg(-1) x d(-1)) or telmisartan (6 mg x kg(-1) x d(-1)) plus pyridoxamine (200 mg x kg(-1) x d(-1), n = 12 each) for 16 weeks. Wistar-Kyoto (WKY, n = 12) rats serve as normotensive control. The systolic blood pressure (SBP) of rat was measured before and weekly thereafter. The serum advanced glycation end-products (AGEs) were detected by competitive ELISA. The serum super oxide dismutase (SOD) and nitric oxide (NO) were measured. The abdominal aorta were assessed by image analysis in HE stained sections. The VSMCs apoptosis and proliferation in abdominal aorta were detected with in situ end labeling technique and proliferating cell nuclear antigen (PCNA) immunohistochemistry staining respectively.
  
  
  RESULTS
  SBP were significantly lower in telmisartan and telmisartan plus pyridoxamine therapy group than in placebo treated hypertensive rats while not affected by pyridoxamine (P > 0.05). Activity of SOD and NO were significantly higher and AGEs significantly lower in telmisartan, pyridoxamine and combination therapy treated SHRs than in placebo treated hypertensive rats (P < 0.01). The telmisartan, pyridoxamine and combination therapy can significantly inhibit the PCNA expression and significantly enhance the apoptosis value in abdominal aorta (P < 0.01). The efficacy of combined treatment was significantly higher than telmisartan and pyridoxamine alone (P < 0.05).
  
  
  CONCLUSIONS
  Telmisartan and pyridoxamine could attenuate abdominal aorta vascular remodeling via reducing oxidative stress and AGEs production as well as restoring the balance of VSMCs proliferation and apoptosis in SHRs abdominal aorta.
authors.affiliation: Fujian Provincial Hospital, Provincial Clinical College, Fujian Medical University, Fujian Institute of Clinical Geriatrics, Fuzhou 350001, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Jiang
authors.forename: Peng-Li
authors.initials: PL
authors.lastname: Zhu
authors.forename: Wei-Ping
authors.initials: WP
authors.lastname: Zheng
authors.forename: Hui-Zhen
authors.initials: HZ
authors.lastname: Yu
authors.forename: Feng
authors.initials: F
authors.lastname: Huang
authors.forename: Fan
authors.initials: F
authors.lastname: Lin
authors.forename: Hong
authors.initials: H
authors.lastname: Lin
authors.forename: Cheng-Ai
authors.initials: CA
authors.lastname: Sun
mesh_terms: D000818:Animals; D001012:Aorta, Abdominal / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D001562:Benzimidazoles / Q000494:pharmacology*; D001565:Benzoates / Q000494:pharmacology*; D001794:Blood Pressure; D049109:Cell Proliferation / Q000187:drug effects*; D017127:Glycation End Products, Advanced / Q000097:blood; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism; D018384:Oxidative Stress; D011733:Pyridoxamine / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D013482:Superoxide Dismutase / Q000378:metabolism; D000077333:Telmisartan
chemical_list: D001562:Benzimidazoles; D001565:Benzoates; D017127:Glycation End Products, Advanced; D009569:Nitric Oxide; D011733:Pyridoxamine; D013482:Superoxide Dismutase; D000077333:Telmisartan